South San Francisco, CA, November 13, 2012 – Prothena Corporation, a biotechnology
company focused on the discovery and development of novel antibodies for the potential
treatment of a broad range of diseases, today announced that the company’s management team
will present a company overview at the Lazard Capital Markets 9th Annual H...
Creates two independent, unique companies
Transaction aligns assets, timelines, and risk/reward
Elan to become immediately profitable and a high growth company
Targeting $1.00 earnings per share by 2015 with new business construct...